QPPV.COM KNOWLEDGE ASSESSMENT

Daratumumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Daratumumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient receiving daratumumab has a positive indirect antiglobulin test and a potential need for urgent transfusion. What is the most appropriate pharmacovigilance interpretation?

The result is a conventional hypersensitivity adverse reaction by definition The result may represent a medication-related laboratory interference with potential transfusion workflow and patient-safety consequences The result proves that the patient has developed a new red-cell alloantibody The result can be ignored because daratumumab does not affect blood-bank procedures

Question 2 of 10 Which periodic benefit-risk assessment is most appropriate as daratumumab use expands into earlier disease settings?

Continue using late-line safety rates without adjustment because the active antibody is unchanged Integrate disease control with infections, cytopenias, administration reactions, immune effects, HBV reactivation, route-specific experience and laboratory-interference controls Evaluate only overall response rate and exclude operational medication-safety risks Replace clinical safety review with analysis of anti-drug antibodies alone

Question 3 of 10 A safety database contains a cluster of transfusion delays coded as laboratory abnormalities, with no product term recorded. What is the most appropriate signal-detection response?

Exclude the cases because they are not coded as adverse drug reactions Retrieve narratives and exposure histories to determine whether CD38-antibody interference contributed Reclassify every laboratory abnormality as hepatitis B reactivation Pool the cases with administration reactions without further review

Question 4 of 10 Which statement best captures the regulatory significance of daratumumab's development history?

All reports involving daratumumab can be interpreted identically regardless of when and why it was used Expansion from heavily pretreated disease to earlier settings and additional indications changes the populations, regimens and background risks represented in safety data Conditional authorisation means later safety data cannot be used in benefit-risk assessment The initial authorisation determines the risk profile for all future presentations and indications

Question 5 of 10 Why can peripheral neuropathy be difficult to attribute to daratumumab in a combination regimen?

Neuropathy is unrelated to all antimyeloma treatments Some combination partners have well-characterised neuropathic toxicity, so phenotype, baseline status, cumulative exposure and treatment changes must be considered Neuropathy can only be caused by viral infection in myeloma The route of daratumumab administration determines all neuropathy causality

Question 6 of 10 Which comparison best illustrates why route should be retained in daratumumab safety analyses?

Intravenous and subcutaneous presentations contain unrelated active substances Route and formulation can alter the pattern and frequency of administration-related reactions and may create different product-use considerations Route is irrelevant because only the disease indication determines all safety outcomes Route should replace the need to record dose dates and concomitant medicines

Question 7 of 10 Which information most strengthens assessment of a serious infection in a daratumumab-treated patient?

The product name without information about immune status or co-medication Infection site and organism, neutrophil count, immunoglobulin status, corticosteroid exposure and concurrent therapy Only whether the patient received intravenous or subcutaneous daratumumab Only the date on which the patient's myeloma was diagnosed

Question 8 of 10 Which approach best evaluates whether transfusion-related risk minimisation for daratumumab is functioning effectively?

Confirm only that the warning appears in the product information Assess whether exposure history reaches blood banks, patients retain alert information and compatibility testing delays or near misses are identified Measure only the number of doses administered Review only spontaneous reports coded as hypersensitivity

Question 9 of 10 Why is the complete treatment regimen essential when assessing cytopenia in a patient receiving daratumumab?

Daratumumab cannot cause or contribute to any cytopenia Cytopenia may reflect baseline marrow disease, daratumumab, another regimen component, or interactions among these factors The only relevant determinant is the daratumumab batch number Cytopenia attribution can be established solely from the date of the last antibody dose

Question 10 of 10 Which pharmacological description most accurately characterises daratumumab?

A soluble-ligand neutralising antibody with no relevant Fc-mediated activity A human IgG1 kappa monoclonal antibody that targets CD38 and can recruit several effector mechanisms A small-molecule inhibitor of plasma-cell immunoglobulin secretion A recombinant enzyme that selectively degrades monoclonal immunoglobulin

Daratumumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings